Clinical Characteristics of AML Patients
| AML FAB Type . | No. of Patients . | Age in Years Median (range) . | Sex (male/ female) . | WBC/μL Median (range) . | Chemotherapy of De Novo AML Patients . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Conventional-150 . | Conventional-150 + Allograft . | Palliative . | Undetermined No. . | |||||||||
| Total . | De Novo . | No. . | CR . | No. . | CR . | No. . | CR . | |||||
| Myeloblastic (M1/M2) | 51 | 44 | 51 (18-83) | 26/25 | 40 (4-417) | 28 | 18 | 3 | 2 | 5 | 0 | 8 |
| Promyelocytic (M3) | 8 | 8 | 39 (22-72) | 4/4 | 20 (2-85) | 4 + 2 Patients also treated with ATRA | 3 | 1 | 1 | 0 | 0 | 1 |
| Myelomonocytic (M4) | 13 | 9 | 49 (14-62) | 10/3 | 52 (8-166) | 7 | 4 | 2 | 1 | 0 | 0 | 0 |
| Monoblastic (M5) | 17 | 17 | 39 (15-70) | 8/9 | 107 (9-242) | 9 | 4 | 4 | 3 | 4 | 0 | 0 |
| Undefined or M7 | 6 | 4 | 37 (33-60) | 3/3 | 7 (0.9-190) | 3 | 1 | 0 | 0 | 1 | 0 | 0 |
| Total | 95 | 82 | 48 (14-83) | 51/44 | 47 (0.9-417) | 53 | 30 | 10 | 7 | 10 | 0 | 9 |
| AML FAB Type . | No. of Patients . | Age in Years Median (range) . | Sex (male/ female) . | WBC/μL Median (range) . | Chemotherapy of De Novo AML Patients . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Conventional-150 . | Conventional-150 + Allograft . | Palliative . | Undetermined No. . | |||||||||
| Total . | De Novo . | No. . | CR . | No. . | CR . | No. . | CR . | |||||
| Myeloblastic (M1/M2) | 51 | 44 | 51 (18-83) | 26/25 | 40 (4-417) | 28 | 18 | 3 | 2 | 5 | 0 | 8 |
| Promyelocytic (M3) | 8 | 8 | 39 (22-72) | 4/4 | 20 (2-85) | 4 + 2 Patients also treated with ATRA | 3 | 1 | 1 | 0 | 0 | 1 |
| Myelomonocytic (M4) | 13 | 9 | 49 (14-62) | 10/3 | 52 (8-166) | 7 | 4 | 2 | 1 | 0 | 0 | 0 |
| Monoblastic (M5) | 17 | 17 | 39 (15-70) | 8/9 | 107 (9-242) | 9 | 4 | 4 | 3 | 4 | 0 | 0 |
| Undefined or M7 | 6 | 4 | 37 (33-60) | 3/3 | 7 (0.9-190) | 3 | 1 | 0 | 0 | 1 | 0 | 0 |
| Total | 95 | 82 | 48 (14-83) | 51/44 | 47 (0.9-417) | 53 | 30 | 10 | 7 | 10 | 0 | 9 |
Abbreviations: FAB, French-American-British classification of AML34,35; CR, complete remission. CR has been determined by cytological examination of BM aspirate.
Conventional chemotherapy refers to treatment with anthracycline and cytarabine.36 Two from the 6 M3 patients have been also treated with ATRA (all-trans retinoic acid).44These two patients have not been considered for the disease-free survival studies. The same was for patients with undefined or M7 AML.